Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRY-box transcription factor 5 (SOX5)
- Target
- SOX5
- Molecular classification
- Transcription factor, SOX (SRY-related HMG-box) family
01
Overview
SOX5 encodes a transcription factor in the SOX (SRY-related HMG-box) family, crucial for embryonic development and regulation of cell fate. It binds DNA at specific motifs and regulates gene expression necessary for chondrocyte differentiation and cartilage formation. SOX5 cooperates with SOX6 and SOX9 on enhancers of cartilage-specific genes, facilitating proper skeletal tissue formation. It also regulates neural development, β-cell identity in the pancreas, and ciliary motility. Mutations or altered expression have been linked to developmental syndromes (like Lamb-Shaffer syndrome), cancer, musculoskeletal disorders, neurodegeneration, diabetes, and inflammation. SOX5 is not a classic drug target, but its role as a transcriptional regulator has made it a focus of experimental therapies employing microRNAs and epigenetic modulators
- Other names
- Transcription factor SOX-5L-SOX5MGC35153L-SOX5BL-SOX5FLAMSHFSRY (sex determining region Y)-box 5SRY-box 5Sox5l1LOC100503149LOC312831A730017D01RIK
02
Mechanism of action
Drug or biologics could act by altering SOX5 expression via RNA interference (miR-132, miR-15a/16, miR-497-5p), indirect modulation of SOX5 function, or epigenetic changes
03
Biological functions
Embryonic developmentcell fate determinationchondrogenesiscartilage formationneural differentiationregulation of β-cell identity (pancreatic function)cilia formationtranscription regulation
04
Disease associations
Cancer (aggressive pituitary tumors, non-small cell lung cancer, hepatocellular carcinoma, breast cancer, osteosarcoma, B cell malignancies)intellectual disabilityLamb-Shaffer syndromecongenital melanocytic nevus syndromechronic back painmusculoskeletal disease (osteoarthritis, osteoporosis)neurodegenerative disease (Alzheimer’s, neurodevelopmental deficit)inflammation (rheumatoid arthritis)cardiac electrophysiological traits
05
Safety considerations
Targeting SOX5 presents risks of impaired embryogenesiscartilage or neural developmentis dosage-sensitiveand may affect broad cell types
06
Interacting drugs
None reported in clinical use
2 more in the full profile.
07
Biomarkers
SOX5 expression level (in brain tumors for immunogenic marker, β-cell function in diabetes)miRNA levels as disease progression biomarkers
Beyond the preview
Go deeper on SRY-box transcription factor 5 (SOX5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRY-box transcription factor 5 (SOX5).